Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
Semaglutide and NAION: What Current Research Shows The July 2024 Harvard study from Massachusetts Eye and Ear found that individuals prescribed Ozempic and other GLP-1 drugs were at a heightened risk for developing NAION
By analysing the FDA database, the study found significantly elevated risks of general vision impairment, retinopathy, and ischaemic optic neuropathy linked to semaglutides compared with other anti-diabetic and weight-loss medicines
ACS Nano 16 (9), 1526115272 (2022)
Robole ZM, Rahn KL, Lampkin BJ, Anand RK, VanVeller B
The major generics are Noveltreat/Sematrinity (Sun Pharma), Obeda/Usema (Dr Reddy's + USV), Semaglyn/Mashema/Alterme (Zydus), Semanext/Livarise (Lupin via Zydus), Semasize/Obesema/Hepaglide (Alkem), GLIPIQ (Glenmark), Sembolic/Semalix (Torrent injectable + oral), Semabest (MSN Labs first integrated made-in-India semaglutide, April 2026 launch), SUNDAE/Semanat/Semafull (Eris/Natco), and Samakind (Mankind)
US$ 20.96
US$ 26.07
US$ 28.82
US$ 29.23
US$ 28.61
US$ 29.32
